Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Intuit Inc. (INTU) vs Viatris Inc (VTRS) Price & Performance

Intuit Inc.Trade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Intuit Inc. vs Viatris Inc — how do they compare? Intuit Inc. trades at $302.75 (market cap $81.21B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Intuit Inc. is far larger — about 4.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 66 Days and Viatris Inc for 57 Days on average.

INTUVTRS
Market Cap
$81.21B$20.03B
Volume
5,165,80614,109,977
Sector
TechnologyHealth
52-Week High
$683.39$18.27
52-Week Low
$255.07$9.74
Typical Hold Time
66 Days57 Days
Enterprise Value
$82.43B$32.15B
Dividend Yield
1.82%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Intuit Inc.

Intuit (INTU) trades at $303.88, up 2.23% today, with strong technical momentum as it approaches resistance near $307. The company demonstrates robust fundamentals with revenue growth from $18.83B in 2025 to projected $21.4B in 2026, net margins expanding to 21.29%, and consistent earnings beats in recent quarters. Analyst consensus remains bullish with a $379.68 price target, though recent class action lawsuits create near-term sentiment headwinds.

INTU presents a compelling growth story with strong profitability and market leadership in financial software. The primary investment opportunity lies in continued QuickBooks and TurboTax monetization, while risks include legal overhang from securities litigation and competitive pressures in the fintech space. Current valuation at 18.46 P/E appears reasonable given earnings growth trajectory.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INTU
25% Buy75% Sell
Avg holding period · 66 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Intuit Inc.

Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.

Read more on INTU →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →